CytRx Corporation announced that it has hired Olivia Ware as its Chief Commercial Officer and a member of its senior executive team. Ms. Ware brings more than 20 years of biotechnology and pharmaceutical experience, including thirteen years at Genentech where she was responsible for key aspects of the launches of the oncology drugs Rituxan®, Herceptin® and Avastin®. While at Genentech, Ms. Ware was a Senior Director of Oncology and was responsible for the initial commercial launch of Avastin in the U.S., which reached $1 billion in sales during its first year on the market. Prior to this, she was head of Herceptin marketing and held a number of other positions in the commercial organization.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | +2.68% | -2.13% | +76.92% |
Jun. 04 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
May. 15 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+76.92% | 1.11M | |
+17.09% | 45.34B | |
+42.10% | 40.42B | |
-9.70% | 37.92B | |
+33.28% | 31.75B | |
-8.98% | 27.71B | |
+13.37% | 26.52B | |
+44.11% | 13.96B | |
+32.33% | 12.44B | |
-7.26% | 11.26B |
- Stock Market
- Equities
- LADX Stock
- News LadRx Corporation
- CytRx Corporation Hires Olivia Ware as its Chief Commercial Officer and Member of Senior Executive Team